Background. Matrix metalloproteinases (MMPs), especially basement membrane-degrading MMP-9 and MMP-2, play an important role in immune-mediated tissue destruction of the allograft by allowing influx of leucocytes and mononuclear cells into the graft. The present study was, therefore, undertaken to investigate the association of functional polymorphisms in MMP-9 (836A>G, 1721G>C and 2003G>A) and MMP-2 (−735C>T) genes with risk of allograft rejection in renal transplant recipients of North India. Methods. Three hundred and six renal transplant recipients categorized into 228 non-rejecters and 78 rejecters were genotyped for MMP-9 and MMP-2 polymorphisms by polymerase chain reaction-restriction fragment length polymorphism methodology. Results. A significant difference in genotype/allele frequencies was observed between healthy individuals in comparison to non-rejecters/rejecters for MMP-9 836A>G, MMP-9 2003G>A and MMP-2 −735C>T. Mutant allele carriers for MMP-9 2003G>A [GA+AA−; odds ratio (OR) = 0.45, 95% confidence intervals (95% CI) = 0.24-0.85, P = 0.014] and MMP-2 −735C>T (CT+TT−; OR = 0.40, 95% CI = 0.18-0.91, P = 0.029) demonstrated significantly reduced risk for allograft rejection. The mean time to first rejection episode was significantly higher in GA/AA and CT/TT genotype recipients for MMP-9 2003G>A (log P = 0.026) and MMP-2 −735C>T (log P = 0.003), respectively. Haplotypes with mutant alleles for MMP-9 1721C>G-2003G>A and mutant allele genotype combinations for both MMP-9 2003G>A and MMP-2 −735C>T conferred significantly reduced risk for allograft rejection. Conclusion. Mutant alleles for MMP-9 2003G>A and MMP-2 −735C>T are associated with reduced risk for allograft rejection and improved allograft survival in North Indian transplant recipients and could serve as an ideal marker to predict pre-transplant allograft outcome.
Introduction
Acute and chronic allograft rejection remains to be one of the crucial impediments in successful renal transplantation. Allograft rejection is characterized by coordinated infiltration of T cells and macrophages, which induce the immune-mediated tissue destruction of the allograft, features associated with qualitative and quantitative alterations in the extracellular matrix (ECM) compartment [1] . The major regulators of ECM turnover are matrix metalloproteinases (MMPs), which represent the major group of zinc-dependent matrix-degrading proteases. Furthermore, MMPs are involved in various pathological conditions associated with cell migration, tissue invasion by lymphocytes and inflammation [2, 3] . In addition, they are also involved in the regulation of the immune response by degradation and activation of several cytokines and chemokines [4] . Therefore, the investigation of the role of MMPs in allograft rejection may lead to better understanding and subsequently newer approaches to combat rejection process.
MMP-2 and MMP-9 of the gelatinases subfamily of MMPs have been widely studied in kidney [5] and in renal transplant models for acute and chronic allograft rejection [6] . MMP-2 (gelatinase A) predominantly degrades fibronectin and laminin, whereas MMP-9 (gelatinase B) degrades collagen Types IV and V [7] . In the kidney, collagen Type IV is present in basal membranes, whereas fibronectin, laminin and collagen Type V constitute the tubulointerstitial matrix [7] . Amongst the several regulating mechanisms influencing MMP activity, such as regulation of transcription, activation of latent MMPs and inhibition of MMP function by tissue inhibitors of metalloproteinases, transcriptional regulation may serve as the most important. Recent evidence indicates that natural sequence variations including single-nucleotide polymorphisms (SNPs) in promoters and coding regions, especially non-synonymous SNPs of the MMP genes, may result in different expression of MMPs in different individuals [8] .
The MMP-9 gene located on chromosome 20q11-q13 encodes the 92-kDa collagenase IV. In the coding region of the MMP-9 gene, 836A>G in exon 6 (rs17576, Gln279Arg), 1721G>C in exon 10 (rs2250889, Pro574Arg) and 2003G>A in exon 12 (rs17577, Arg668Gln), resulting in missense amino acid substitution and thus influencing the substrate and inhibitor binding capacity, have been widely studied in various cancers and other diseases [9] . The MMP-2 gene encoding 72-kDa collagenase IV is located on chromosome 16q21. Recently, −735C>T (rs2285053), a sequence variant in the promoter region in MMP-2, leading to reduced promoter activity and thereby reduced gene expression, has been associated with gastric cardia adenocarcinoma [10] . The functional relevance of these SNPs, however, has not been determined in patients with allograft rejection.
Recent studies have demonstrated increased expression of MMP levels associated with heart, lung and kidney allograft rejection [11, 12] . However, to date, no reports are available showing the influence of functional gene polymorphisms in these MMPs on allograft rejection. The present study was, therefore, designed to study the impact of MMP-9 and MMP-2 gene polymorphisms on allograft rejection in renal transplant recipients of North India.
Materials and methods

Study population
A total of 306 transplant recipients from North India (particularly Lucknow and the adjoining cities of North India), who underwent live donor related renal transplant at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India during July 2004-July 2008, were recruited as study subjects in the present study. Selection for transplantation was based on ABO blood group compatibility, a negative complement-dependent cytotoxicity cross-match using all historic positive and current sera and no prior cytomegalovirus infection episodes for either transplant recipients or the donors. Patients were molecular typed for human leucocyte antigen (HLA) class I (A, B and C) antigens and class II (DR and DQ) antigens. The demographic data regarding donor's age and sex and recipient's age, sex, body weight, cause of renal disease, serum creatinine, HLA mismatches, rejection episodes and time to first rejection episode were referred from the hospital records with the assistance of a collaborating renal transplant surgeon. Patients received cyclosporine (CsA; Neoral, Novartis Pharmaceuticals Corporation, Switzerland) or tacrolimus (Tac; Pangraf, Panacea Biotec Ltd, New Delhi, India) formulation as part of their immunosuppressive treatment. Besides the 306 transplant recipients, 81 matched live related kidney donors and 200 unrelated healthy individuals of similar ethnicity who were randomly selected from the hospital staff, students and blood donors visiting the hospital were also included in the study cohort.
Immunosuppressive regimen
Immunosuppressive treatment of the patients consisted of a combination of CsA/Tac as a calcineurin inhibitor with mycophenolate mofetil (MMF)/ azathioprine as a purine inhibitor and prednisolone as a steroid. Out of the total, 231 recipients were on CsA-based and 75 were on Tac-based immunosuppression therapy. The initial dose of CsA and Tac was 8 mg/kg/day and 0.16 mg/kg/day twice a day, respectively. Later, CsA administration was adjusted to target C 2 level (whole-blood CsA level 2-h post-morning dose) in the range of 1.70-1.75, 1.60-1.65, 1.30-1.35, 0.8-1.0 and 0.5-0.6 μg/mL at 1 week, 1 month, 3 months, 6 months and 12 months posttransplantation, respectively. The mean C 2 level of transplant recipients at 1 and 3 months post-transplantation was 1.62 ± 0.14 and 1.33 ± 0.23 μg/ mL, respectively. In recipients on Tac therapy, the oral Tac dose was adjusted to a target T 0 level (whole-blood Tac level just prior to morning dose) in the range of 12-15, 10-12, 8-10, 6-8 and 4-6 ng/mL at 1 week, 1 month, 3 months, 6 months and 12 months, respectively. The mean T 0 level was 10.47 ± 4.99 and 10.23 ± 5.14 ng/mL at 1 and 3 months, respectively. The initial dose of MMF was 1000 mg twice a day, followed by 500 mg twice a day after 1 week and 360 mg twice a day at 3 months post-transplantation. Prednisolone was administered according to a tapering schedule, which involved 500 mg of intravenous methylprednisolone at the time of surgery, 125 mg intravenously the following day and then 20 mg of prednisolone daily.
Clinical data collection
Allograft outcome based on rejection episode and stable graft function of all the recipients was further recorded. The transplant recipients experiencing one or more biopsy-proven rejection episode were grouped as rejecters, whilst the recipients in the non-rejecters group did not have any rejection episode. Before biopsy, clinical rejection was identified as an increase in creatinine level of 10-25% from the postoperative baseline in the absence of other causes of graft dysfunction such as infection, obstruction or evidence of drug toxicity, associated with a fall to within 10% of the baseline creatinine level after administration of anti-rejection treatment. All biopsies were reviewed by a renal pathologist, and the Banff 97 working classification criteria was used in the histological classification of biopsies [13] . According to the Banff 97 criteria, biopsies with Grades IA and IB were considered as cellular rejection and with Grades IIA, IIB and III as vascular rejection. Treatment for rejection episode consisted of intravenous methylprednisolone for 3 days in acute cellular rejection or anti-thymocyte globulins in the event of antibody-mediated rejection/vascular rejection. Recently, antibody-mediated rejection or acute vascular rejection is also being confirmed by immunofluorescence by detecting CD4-positive cells. Rejecters included recipients experiencing both acute (rejection within the first 3 months post-transplant) and chronic (rejections within the first 3 years post-transplant) rejections in the clinical follow-up period. In the present study, 78 (25.5%) patients experienced biopsy-proven acute (n = 69)/chronic rejection (n = 9) during the posttransplant period. Amongst the acute rejecters, 17 biopsies were considered as acute cellular rejection and 52 as vascular rejection. The median follow-up of the renal transplant recipients was 24 months (mean followup of 36.5 months). Maximum follow-up was taken as 48 months and minimum follow-up was 2 months. The protocol was approved by the Institution Ethics Committee and informed consent was obtained from all subjects.
Determination of genotypes
Five-millilitre blood samples were drawn from each subject in an ethylenediaminetetraacetic acid-containing vacutainer tube. Genomic DNA was extracted from peripheral leucocytes by the salting out method and kept at −20°C until use [14] . The 836A>G in exon 6 (rs17576, Gln279Arg), 1721G>C in exon 10 (rs2250889, Pro574Arg) and 2003G>A in exon 12 (rs17577, Arg668Gln) SNPs of the MMP-9 gene were amplified using primer sequences as described previously [9, 15] and genotyping was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The restriction enzymes used for genotyping 836A>G, 1721G>C and 2003G>A were SmaI, BamHI and TaqI, respectively (Fermentas Inc., Glen Burnie, MD). The −735C>T SNP (rs2285053, promoter region) in the MMP-2 gene was amplified using the forward primer 5′-GGATTCTTGGCTTGGCG-CAGGA-3′ and reverse primer 5′-GGGGGCTGGGTAAAAT-GAGGCTG-3′ as described by Li et al., yielding a PCR product of 391 bp [10] . The HinfI restriction enzyme used for genotyping produced fragments of 338 and 53 bp for mutant (TT) genotypes. Based on the size of DNA fragments obtained after restriction enzyme digestion, 10-15% polyacrylamide gel electrophoresis was used for genotyping. Bands were then detected by UV transilluminator after ethidium bromide staining. To improve the genotyping quality and validation, the laboratory personnel were blinded to the samples and 10% of the samples were randomly replicated for other similar studies. The results were reproducible and >99% concordance in genotyping was observed.
Statistical analysis
Each polymorphism was tested for Hardy-Weinberg equilibrium via chisquare goodness of fit. Power of the study was calculated using the Quanto programme version 1.1 (http://hydra.usc.edu/gxe) with input of the fol-3394 R. Singh et al.
lowing variables: significance level < 0.05 (two-sided), model of inheritance = log additive, minor allele frequency = 0.15, genetic effect [odds ratio (OR)] ≤0.6 or ≥1.6. The present study achieved 80% of power which was sufficient to consider an OR of ≤0.6 or ≥1.6. Haplotypes of each individual for the three SNPs in MMP-9 was constructed, and the maximal likelihood haplotype frequencies were estimated using the expectation-maximization algorithm using the Arlequin programme version 2.0. Multiple logistic regression analysis was used to predict the association of MMP-9 and MMP-2 SNPs and MMP-9 haplotypes with allograft rejection, and risk was expressed as ORs with 95% confidence intervals (95% CI). ORs were adjusted for age, gender and body weight status of the subjects. Time-to-event analysis was performed using Kaplan-Meier estimates and log-rank test. Time of occurrence of first rejection episode has been defined as an event. Cox regression analysis was performed to calculate the hazard associated with different genotypes/haplotypes [hazard ratio (HR)]. P-values < 0.05 (two-sided) were considered significant. All the statistical analysis were performed using the SPSS version 11.5 software (Chicago, IL).
Results
Clinical and demographic details of transplant recipients
All 306 transplant recipients recruited were available for genotyping and complete data analysis. The demographic and clinical details of the recipients are presented in Table 1 . The patients were categorized into rejecters and nonrejecters based on the occurrence of biopsy-proven rejection episodes. Out of the total, 78 recipients were grouped into the rejecters category. No significant difference for any of the confounding factors like age or gender status of donors or recipients, body weight, serum creatinine or HLA mismatches and immunosuppressant levels amongst rejecters and non-rejecters were observed in the present study cohort. A comparator group of healthy individuals (n = 200) were also genotyped to analyse the difference in genotype frequency of MMP-9 and MMP-2 SNPs amongst healthy individuals, non-rejecters and rejecters. The variant allele frequency of MMP-9 836A>G was significantly different between healthy individuals and non-rejecters (33.5 vs 46.5%; P < 0.001) as well as between healthy individuals and rejecters (33.5 vs 45.5%; P= 0.008). For MMP-9 2003G>A, the genotype frequency differed significantly between healthy individuals and non-rejecters (P= 0.020) as well as between healthy individuals and rejecters (P = 0.008), although no significant difference in allele frequency was observed. For MMP-2 −735C>T, a significant difference in genotype and allele frequency was observed between healthy individuals and rejecters (Table 2) .
Since donor renal cells also produce MMPs, we, therefore, performed genotype analysis in 81 matched live related kidney donors for 81 transplant recipient pairs from our transplant study cohort and compared these results to the genotypes of the recipients. Table 3 represents the genotype frequency distribution between donor and recipient pairs on the basis of allograft rejection. Although no significant association for allograft rejection was observed either in transplant recipients or their matched donors, a decreasing trend of lower variant allele frequency amongst rejecters in both donors and recipients was observed for all the three MMP-9 SNPs analysed.
Influence of MMP-9 and MMP-2 gene polymorphisms on allograft rejection
The genotype and allele frequency distribution of three polymorphic sites in MMP-9 (836A>G, 1721C>G and 2003G>A) and one in MMP-2 (−735C>T) amongst rejecters and non-rejecters is represented in Table 4 . The geno- MMP-9 and MMP-2 gene polymorphism and allograft rejection 3395 type distribution in studied subjects followed the HardyWeinberg equilibrium. In MMP-9, 2003G>A SNP showed significant association with allograft rejection. A lower prevalence of mutant (A) allele carriers (GA+AA) was ob- ence of the allele, with allele A showing reduced risk for allograft rejection. The prevalence of mutant T allele carriers (CT+TT) for −735C>T in MMP-2 was significantly lower in rejecters compared to non-rejecters, showing protective association with allograft rejection (OR = 0.40, 95% CI = 0.18-0.91, P = 0.029). The other two SNPs in MMP-9 did not show any significant differences in genotype or allele frequencies between rejecters and non-rejecters. Since allograft survival is also influenced by the type of acute rejection, we, therefore, also analysed the influence of these MMPs on the basis of antibody-mediated rejection and cellular rejection. Out of the total 69 recipients experiencing acute rejection, 52 were of the antibody-mediated type and 17 were of the cellular type. Amongst the different MMPs, the recipients with either heterozygous or homozygous variant genotype of MMP9 1721C>G SNP demonstrated a 3.75-fold increased risk for cellular-mediated rejection compared to antibody-mediated rejection (OR = 3.75, 95% CI = 1.18-11.84, P = 0.024; Table 5 ).
Survival functions of the allograft and MMP-9 and MMP-2 gene polymorphism
The Cox proportional hazards model was used to analyse the influence of MMP-9 and MMP-2 SNPs on allograft MMP-9 and MMP-2 gene polymorphism and allograft rejection 3397 outcome using months to first rejection episode as the dependent variable and genotypes and other covariates as independent variables. The results show a similar trend as observed in the logistic regression model. Significantly reduced risk for allograft rejection was observed in mutant allele carriers (GA+AA) of MMP-9 2003G>A compared to GG genotype recipients (HR = 0.49, 95% CI = 0.28-0.87, P = 0.014) (Table 4) . Similarly, for MMP-2 −735C>T, CT or TT genotype recipients were associated with reduced risk for allograft rejection (HR = 0.44, 95% CI = 0.21-0.92, P = 0.030). Furthermore, KaplanMeier survival analysis was conducted to assess the mean time to first rejection episode between different genotype groups of patients. In confirmation of the above findings, the recipients with GA/AA genotype for MMP-9 2003G>A demonstrated higher mean time to first rejection episode compared to GG genotype patients (39.02 ± 1.58 vs 34.51 ± 1.60 months, log P-value = 0.026; Figure 1A ). The CT/TT genotype recipients for MMP-2 −735C>T also showed higher mean time to first rejection episode compared to CC genotype recipients (42.53 ± 1.82 vs 34.69 ± 1.36 months, log P-value = 0.003; Figure 1B) . When the combined effect of MMP9 2003G>A and MMP2 −735C>T SNPs on mean survival time was analysed, the wild-type genotypes (GG and CC) demonstrated a significantly reduced mean survival time of 32.04 ± 1.93 months compared to other combinations (log P-value = 0.001; Figure 1C ).
Influence of MMP-9 and haplotypes and MMP-9 and MMP-2 genotype combination on allograft rejection
Since all three SNPs in MMP-9 were in linkage disequilibrium, haplotype analysis was done to study the influence of MMP-9 haplotypes on allograft rejection. Table 6 Since mutant allele carriers for both MMP-9 2003G>A and MMP-2 −735C>T demonstrated significantly reduced risk for allograft rejection, we made different genotype combinations of MMP-9 2003G>A and MMP-2 −735C>T and then analysed the influence of these combinations on allograft rejection. In total, four combinations were made, taking wild-type and mutant allele carriers for both the SNPs. The wild-type genotype for both SNPs was taken as reference. All the combinations having mutant allele carriers for either of the two SNPs were associated with reduced risk for allograft rejection. Significantly reduced risk was observed in patients with MMP9 2003GA/AA + MMP2 −735CT/TT with OR = 0.16, 95% CI = 0.04-0.75, P = 0.020 (Table 7) .
Discussion
In solid organ transplantation, multiple studies have demonstrated that MMPs are involved in allograft tissue injury, including ischaemia-reperfusion injury [16] and acute or chronic rejection [17, 18] . Although not proven, it can be speculated that the MMPs play a major role in the degradation of basement membranes that allows influx of leucocytes and mononuclear cells into the inflammatory site of the graft.
The present molecular epidemiologic study examined whether genetic polymorphisms in MMP-9 and MMP-2 were associated with the occurrence of the risk of allograft rejection in renal transplant recipients. We observed that the mutant allele carriers, GA+AA for MMP-9 2003G>A and CT+TT for MMP-2 −735C>T SNPs, were associated with significantly reduced risk for allograft rejection compared to recipients having the wild-type genotype for these SNPs. Furthermore, the Kaplan-Meier survival analysis indicated a higher mean time to first rejection episode in GA or AA genotype carriers (39 months) compared to GG genotype (34 months) for MMP-9 2003G>A (log P = 0.026). Similar observations were also recorded for MMP-2 −735C>T, showing that the mean time was 42 months for mutant allele carriers (CT/TT) compared to 34 months in the CC genotype (log P = 0.003). These observations suggested that the mutant allele carriers for both polymorphisms had a beneficial effect and thus reduced susceptibility for allograft rejection in our North Indian cohort of renal transplant recipients.
Polymorphisms in the coding regions of MMP-9 have been associated with the risk of cancer and other inflammatory diseases since the variants of the gene may change the expression or function of the protein [19] . The 836A>G polymorphism, commonly referred to as MMP-9 and MMP-2 gene polymorphism and allograft rejection 3399 Q279R, occurs in the coding region within the fibronectin Type II domains that play important roles in substrate binding [20] . The 1721C>G and 2003G>A polymorphisms, commonly referred to as P574R and R668Q, respectively, are also located in the coding region of the gene, which are in the hemopexin domain and are thought to affect both substrate and inhibitor binding [21] . Therefore, these polymorphisms potentially alter the protein structure of MMP-9 and may have some functional relevance and affect an individual's susceptibility to allograft rejection. The significantly reduced risk for allograft rejection inferred by mutant allele carriers (GA+AA) for 2003G>A (R668Q) in the present study suggested that substitution of arginine by glutamine may have resulted in reduced substrate and inhibitor binding and, therefore, reduced MMP-9 expression subsequently resulting in reduced proteolytic cleavage of basement membrane, the major cause of allograft rejection. Although no other studies correlating the influence of this polymorphism on allograft rejection are available, a recent study in non-small cell lung cancer patients demonstrated improved median survival time in 2003A (668Gln) allele carriers (51.6 months) compared to wild-type genotype patients (21.8 months) (log-rank P = 0.010) [22] . No significant association with the other two polymorphisms (836A>G and 1721C>G) in MMP-9 was observed. Furthermore, to analyse the combined effect of all the three polymorphisms in MMP-9, haplotypes 836A-1721C-2003A and 836A-1721G-2003G, carrying the mutant allele for either 1721C>G (P574R) or 2003G>A (R668Q), had significantly reduced risk for allograft rejection.
MMP-2 −735C>T transition located at a core recognition sequence of Sp1 (CCACC box) leads to a strikingly low promoter activity due to the abolishment of the Sp1 binding site [23] . In the present study, the mutant allele carriers (CT +TT) associated with significantly reduced risk for allograft rejection suggested that T alleles may be associated with reduced MMP-2 expression. This is supported by available reports which suggest increased MMP2 levels in rejected allograft [24] . A recent study by Wu et al. suggested that the mean recurrence-free survival of hepatocellular carcinoma after liver transplantation for the CT genotype was significantly longer than that for homozygous CC patients (30.4 vs 19.3 months, P = 0.019) [9] .
MMP-2 and MMP-9, members of the gelatinases subfamily, have been most widely associated with allograft rejection, suggesting a significantly increased gelatinase expression at the time of rejection. Recently, MMP-2 and MMP-9 have been suggested to play a critical role in the development of tissue remodelling and fibrosis in the renal and liver allograft [6, 25] . Moreover, since in the present study the majority of rejections are due to acute vascular rejection, which are characterized by mild to severe intimal or transmural arteritis/arterial fibrinoid changes, it can be hypothesized that MMPs play a major role in macrophage infiltration due to tissue remodelling and fibrosis, a characteristic of vascular rejection. Yamani et al. also suggested enhanced MMP levels in 14 heart transplant recipients with acute vascular rejection [11] . In contrast, in the present study, the analysis of the distribution of MMPs on the basis of antibody-mediated and cellular rejection suggested a significantly increased risk for cellular rejection in rejecters with variant allele for MMP9 1721C>G which may be explained due to the small number of rejecters with cellular rejection in our study cohort.
Thus, our findings demonstrating enhanced allograft survival in mutant allele carriers for MMP-9 2003G>A and MMP-2 −735C>T may offer an opportunity to predict pre-transplant allograft outcome and subsequently for complementary therapy of allograft rejection. Moreover, a significant difference was observed between genotype/allele frequencies for MMP-9 836A>G, MMP-9 2003G>A and MMP-2 −735C>T between healthy individuals with nonrejecters and rejecters in a separate comparison. Difference in frequency between healthy-non-rejecters and healthy rejecters indicates an important role of MMPs in end-stage renal disease patients. Nevertheless, these findings need to be validated in functional studies of the genetic variants and additional multi-centric studies with larger sample size and diverse ethnic populations. Furthermore, the multiplicity of control mechanisms of MMP activity may be dependent on transcription regulation. Nevertheless, compartmentalization by pericellular accumulation, activation by cleavage of latent pro-enzymes and inhibition by specific proteins cannot be ignored. Since MMP activity also influences cytokine and chemokine production, interactions with cytokine and chemokine gene polymorphisms should be explored as it is likely that variants of these genes that are important in allograft rejection substantiate the effect of the SNPs studied.
Conclusion
In conclusion, the present pilot study has provided evidence that the genetic variant in 2003G>A (R668Q) of MMP-9 and −735C>T of MMP-2 polymorphisms is associated with reduced risk for allograft rejection in renal transplant recipients of North India. To our knowledge, this is the first study demonstrating the influence of genetic polymorphisms in MMP-9 and MMP-2 on allograft rejection.
